How to Sequence Therapies in Peripheral T Cell Lymphoma.
Kitsada WudhikarnN Nora BennaniPublished in: Current treatment options in oncology (2021)
Peripheral T cell lymphoma (PTCL) represents a heterogeneous group of rare lymphoproliferative disorders. Historically, there has been a lack of pathobiological understanding of PTCL. With the exception of ALK-positive anaplastic large cell lymphoma, patients with PTCL have less favorable outcomes, with most patients relapsing shortly after conventional anthracycline-containing multi-agent chemotherapy. The standard management approach for PTCL involves induction therapy followed by autologous stem cell transplantation. Patients with relapsed/refractory PTCL have dismal outcomes and limited treatment options despite the available novel agents, therefore remaining a critical unmet need. By virtue of advancement in cancer biology over the recent years, the treatment landscape of PTCL has gradually evolved from conventional chemotherapy based on solely morphological diagnosis toward more individualized therapies by integrating molecular attributes of PTCL to the traditional treatment paradigm. We are at the edge of witnessing a paradigm shift in PTCL management.
Keyphrases
- stem cell transplantation
- end stage renal disease
- high dose
- diffuse large b cell lymphoma
- single cell
- chronic kidney disease
- chemotherapy induced
- squamous cell carcinoma
- epstein barr virus
- young adults
- type diabetes
- ejection fraction
- rheumatoid arthritis
- metabolic syndrome
- adipose tissue
- mesenchymal stem cells
- papillary thyroid
- low dose
- glycemic control
- tyrosine kinase
- single molecule
- hodgkin lymphoma
- advanced non small cell lung cancer
- patient reported
- smoking cessation
- rectal cancer